1 Super Growth Stock Down 63% to Buy Hand Over Fist in 2025

Leading organ transplant technology provider TransMedics (TMDX 3.90%) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth of "only" 64% in its latest quarter -- while lowering guidance for a 35% increase in the upcoming fourth quarter -- the company has seen its stock plummet roughly 63% from its highs.As substantial as TransMedics' stock sell-off has been, its underlying business is by no means 63% worse. And remember, this adverse ...